Ignacio Anegon, INSERM UMR 1064-Center for Research in Transplantation and Immunology, Labex Immunology Graft Oncology, FOCIS Center of Excellence Nantes University

Ignacio ANEGON
Dr. Anegon is an INSERM Director of Research. He is based at the INSERM-CRTI laboratory in Nantes where he is co-head of a team and Director of rat transgenesis platform. His work is centered on the development of immune tolerance strategies in solid organ transplantation, GVHD and autoimmune diseases. He has also generated numerous genome-edited rat models.

Jeffrey Bluestone, UCSF and Parker Foundation, USA

Jeff BLUESTONEJeffrey Bluestone, PhD, is the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and is the Director of the Hormone Research Institute in the Diabetes Center. His research over the past 25 years has focused on understanding the basic processes that control T cell activation and immune tolerance in autoimmunity and organ transplantation. He and members of his lab have developed soluble receptor antagonists; monoclonal antibodies and animals deficient in individual members of TCR and co-stimulatory pathways to define their individual roles in transplant rejection and autoimmunity including a special emphasis on a specialized subset of T cells termed “regulatory T cells” (Treg). Tregs control fundamental aspect of immune homeostasis. During the last several years, his research has adapted the animal studies using biologics and cell based therapies to develop therapeutics that can be used in humans with autoimmunity and under conditions of allotransplant rejection. Moreover, a strong role for antigen-specific Tregs have been found in these model systems and further evidence in humanized mice and transplant patients that alloantigen-specific Tregs are more effective. Thus, the major goal of this work is to identify the antigen-specificity of thymic- and peripherally-derived Tregs with the expectation that these TCRs can be adapted for immunotherapy. Finally, his lab initiated several projects to determine mechanisms that control Treg stability. The goal is to develop approaches using pharmacogenomics to either stabilize or destabilize Tregs in autoimmunity and cancer.

Nicolas Damond, Bodenmiller Lab, Department of Quantitative Biomedicine, University of Zurich, Switzerland

Nicolas DAMONDNicolas Damond graduated from the University of Lausanne with an MSc in Genomics and Experimental Biology and received his PhD in Biology from the University of Geneva in 2015. Currently, he is working as a postdoctoral researcher in the lab of Prof. Bernd Bodenmiller at the University of Zurich. He has a long-standing research interest in the study of pancreatic islets in the context of type 1 diabetes. During his thesis work, he used transgenic mouse models and primary human islets to study islet cell type conversion after massive destruction of insulin-producing beta cells. He is now using Imaging Mass Cytometry to profile samples from donors with type 1 diabetes with the objective of reconstructing the parallel evolution of beta cells and islet-infiltrating immune cells through disease progression.
Jean-François Fonteneau, CRCINA, INSERM U1232, Labex IGO, Siric ILIAD, Nantes

JF FonteneauDuring his PhD, Jean-François Fonteneau studied T cells response against melanoma in Pr Jotereau lab, Nantes, France (1996-99). He joined Dr Bhardwaj in Dr Steinman Lab at Rockefeller University (1999-2003), where he studied DC biology, notably cross-presentation of viral and tumor Ag. He returned to Pr Jotereau Lab to identify melanoma Ag recognised by patients T cells (2003-08). In 2009, he joined Dr Gregoire Lab, INSERM U892, to study attenuated measles virus as an oncolytic virus for virotherapy of pleural mesothelioma.

Muzlifah Haniffa, Wellcome, Lister Institute, Newcastle Biomedical Research Centre, Institute of Cellular Medicine, Newcastle University, UK

Muzlifah HANIFFA Muzlifah Haniffa is a Wellcome Trust Senior Research Fellow, Lister Institute Research Fellow and Consultant Dermatologist based in Newcastle University.  She graduated from medical school in Cardiff and trained as a junior doctor in Cambridge.  She received her dermatology specialist training in Newcastle.  She was awarded an Action Medical Research Training Fellowship and a Wellcome Trust Clinical Intermediate Fellowship.  Muzz was the recipient of the Academy of Medical Sciences Foulkes Foundation Medal (2019) and the European Federation of Immunological Societies ACTERIA Prize in Immunology and Allergology (2018).

Muzz is a leading member of the Human Cell Atlas initiative and pioneered the application of single cell genomics to decode the developing human immune system, and the human skin in health and disease.  

Download a recent article about Muzlifah from the journal Nature.com


Ofer Mandelboim, Institute of Medical Research Israel-Canada (IMRIC), University of Jerusalem, Israel

Ofer MANDELBOIM Ofer Mandelboim is Professor of Molecular Immunology at The Lautenberg Center for General and Tumor Immunology, part of The Hebrew University, Hadassah Medical School.  He is a member of the Israeli Society of Immunology and the American Society of Immunology and is an editorial board member of Placenta, Frontiers in Immunology, Frontiers in Microbial Immunology, and the journal Science in China Series C: lifeScience. Dr Mandelboim is also an editorial member of the American Society of Reproductive Immunology journal. He has received several awards, including The Keye Award in 2015 and the Teva award for immunological research.

Alexander Marson, University of California, San Francisco, USA

Alexander Marson UCSF Alex Marson completed medical school at Harvard, PhD training at the Whitehead Institute/MIT with Richard Young and Rudolf Jaenisch, Internal Medicine residency at the Brigham and Women’s and clinical training in Infectious Diseases at UCSF. He was a UCSF Sandler Faculty Fellow from 2013–2016. Marson is now an associate professor in the UCSF Department of Microbiology and Immunology, with joint appointments in the Department of Medicine and the Diabetes Center. He is also affiliated with the UCSF Helen Diller Cancer Center and a member of the Parker Institute for Cancer Immunotherapy (PICI). He is the scientific director of biomedicine at the Innovative Genomics Institute (IGI) and was selected as one of the inaugural Chan Zuckerberg Biohub investigators. His lab integrates systems-scale investigations of human T cell circuitry with functional perturbation studies, including genome editing in primary T cells.

Renato Monteiro, Center  for  Research  on  Inflammation - INSERM  U1149  &  CNRS  ERL8252 / Paris  Diderot Faculty of Medicine

Renato MONTEIRORenato  Monteiro  is  professor  of  Immunology  at  Paris  Diderot  University  and  head  of  the   Center  for  Research  on  Inflammation  -  INSERM  U1149  &  CNRS  ERL8252  located  at  Bichat   Hospital  campus  in  Paris.  After  obtaining  his  medical  degree  in  Brazil  and  then  completing   a  residency  in  nephrology,  he  moved  to  Paris  in  1982  to  study  nephrology  at  the  Necker   Hospital  under  the  mentoring  of  Professor  Jean  Berger.  Prof.  Monteiro  was  awarded  the   1986  Prize  of  the  French  Society  of  Nephrology  for  his  work  on  IgA  nephropathy,  notably   for  the  identification  of  abnormal  IgA  in  Berger’s  disease.  He  later  studied  immunology  at   the  University  of  Birmingham  in  Alabama  with  Professor  Max  Cooper.  Prof.  Monteiro’s   work  in  Prof.  Cooper’s  lab  led  to  the  identification  of  the  IgA  Fc  receptor  I  (CD89).  He   defended  his  PhD  thesis  in  immunology  in  1993  at  Paris  Diderot  University.

Jordi Ochando,  Icahn School of Medicine at Mount Sinai, New York City, USA

Jordi OCHANDODr. Jordi Ochando is an Assistant Professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai in New York (USA). His laboratory has recently discovered that trained immunity represents a previously unrecognized pathway that prevents the induction of transplantation tolerance. To prevent the detrimental effects of trained macrophages, his laboratory uses a novel revolutionary targeted therapeutic delivery approach, in which drug-loaded nanobiologics that specifically target macrophages in vivo and induce long-term allograft acceptance with minimal immunosuppressive drug usage. This research represents a compelling framework for developing novel targeted therapies that modulate the innate immune response with the concomitant clinical applications in humans.
Eliane Piaggio, Translational immunotherapy team U938, Institut Curie, Paris

Eliane PIAGGIODr. E. Piaggio obtained the diploma of clinical biologist and the PhD in Immunology at the National University of Rosario, Argentine. She did her post-doctoral studies in France and actually is research director of INSERM. She directs the "Translational Immunotherapy team” at Institut Curie, in Paris. Her team is part of the first French Center for Cancer Immunotherapy.  Her main contributions have been in the field of regulatory T-cell based immunotherapy of infectious diseases (Chagas' disease), autoimmunity (type 1 diabetes and multiple sclerosis/EAE), alloreactivity (GVHD and transplantation) and more recently, cancer. Her team is interested in the development of novel immunotherapies, translatable to patients.

Now working in biotechnology with a focus on cancer immunotherapy, Dr. Turley applies principles established in rigorous basic science to making real-life medicines that positively impact cancer patient outcomes. She also continues her mentorship of trainees including postdoctoral fellows and students at the graduate and undergraduate levels.

Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA

Stanley RIDDELL Dr. Riddell is a Member at the Fred Hutchinson Cancer Research Center, Professor, Department of Medicine at the University of Washington, and Distinguished Affiliate Professor at the Technical University of Munich. He is the Virginia Hobbs Charitable Trust Research Professor of the American Cancer Society. His work has focused on the development and clinical translation of T cell therapy for can

Barbara Seliger, Institute for Medical Immunology at the Martin-Luther-University Halle-Wittenberg, Germany

Barbara Seliger Professor Dr. Barbara Seliger is the Director of the Institute for Medical Immunology at the Martin-Luther-University Halle-Wittenberg, in Halle, Germany, Director of a FOCIS Center of Excellence, member of the World Immunoscore and SITC biomarker initiatives. In addition she is head of the work group for “Tumor immunology” of the German Society of Immunology. Prof. Seliger’s research team studies the molecular events associated with immune escape of tumors, the role of the tumor micro-environment and immune cell subpopulations for tumor development and therapy resistance. In addi-tion, her laboratory is involved in optimization and monitoring immunotherapies and in the characteri-zation of biomarkers allowing the prediction of their success. Recently, she became interested in the identification, functional characterization and clinical relevance of immune regulatory microRNAs and RNA-binding proteins as their implementation as therapeutic tools as well as in the role of the tumor and immune cell metabolism in immune surveillance and its modulation as novel therapeutic option alone or in combination with targeted or immunotherapies.

Antonio Sica,  Dept of Pharmacological Sciences, University of Eastern Piedmont, Novara / Head lab. Molecular Immunology, Humanitas Clinical and Research Center , Milan, Italy

Antonio SICA Antonio Sica graduated in Biological Sciences and has subsequently obtained a Ph.D. in Immunology. He worked for several years at the Department of Immunology of the Institute of Pharmacological Research “Mario Negri”, where he served as head of the unit of “gene expression”. In 1990 he joined the National Cancer Institute in Frederick, Maryland, United States of America, where he worked in the section of Molecular Immunology. In 1995, upon his return to Italy, he became head of the Laboratory of Molecular Immunology at the Mario Negri Institute in Milan, focusing on the mechanisms underlying the association between inflammation and cancer development. Since 2005 he is Head of the laboratory of Molecular Immunology, at the Humanitas Clinical and Research Center. He has a long standing interest in the molecular mechanisms that control the functions and the roles of myeloid cells in the development of cancer. His scientific contribution is documented by more than 150 scientific publications in international peer-reviewed journals (H index= 66).

Shannon J. Turley, Department of Cancer Immunology, Genentech, South San Francisco, USA

Shannon TURLEY Dr. Shannon Turley received her PhD in Cell Biology from the Yale University School of Medicine in 1999. After teaching on the faculty in the Department of Biology at Bowdoin College for the 1999-2000 academic year Dr. Turley moved to Harvard Medical School where she carried out postdoctoral training in Immunology and Immunogenetics at Joslin Diabetes Center. Dr. Turley was recruited to the Department of Cancer Immunology and AIDS at Dana Farber Cancer Institute of Harvard Medical School as Assistant Professor in 2004 and promoted to Associate Professor in 2010. Focusing on immunology research at Harvard, Shannon established an international reputation as an expert in stromal immunobiology. During most of her tenure on the faculty, Dr. Turley served as the Associate Director of the PhD Program in Immunology. Throughout her career Dr. Turley has enjoyed teaching and mentoring trainees at the postdoctoral, graduate, undergraduate and high school levels.

In 2014, Dr. Turley was recruited to the Department of Cancer Immunology at Genentech as a Principal Scientist and Group Leader to build a tumor microenvironment/stromal immunobiology discovery research program with a focus on developing immunotherapeutics for treating patients with inflammatory diseases and advanced and metastatic cancers. In 2018 she was promoted to Staff Scientist at Genentech. Dr. Turley presently serves as a permanent member of the NIH Transplantation, Tolerance and Tumor Immunology Study Section and reviews grant applications for research foundations. She also serves on the editorial board for several journals including Journal of Experimental Medicine, Cancer Immunology Research and Scientific Reports. Dr. Turley has published over 115 peer-reviewed papers, invited reviews and book chapters and frequently lectures and presents her published research at conferences and universities around the world. She has been the recipient of a number of awards and honors. Dr. Turley was recently selected to receive the Frederick W. Alt Award for New Discoveries in Immunology from the Cancer Research Institute.

Now working in biotechnology with a focus on cancer immunotherapy, Dr. Turley applies principles established in rigorous basic science to making real-life medicines that positively impact cancer patient outcomes. She also continues her mentorship of trainees including postdoctoral fellows and students at the graduate and undergraduate levels.

Éric Vivier, Aix Marseille University, APHM, CNRS, INSERM, CIML / Hôpital de la Timone, Marseille-Immunopole / Innate Pharma Research Laboratories, Marseille, France
Éric Vivier, DVM, PhD, is Professor of Immunology at Aix-Marseille University and at the Public Hospital of Marseille (AP-HM). In addition, he was appointed in 2018, Scientific Director of Innate Pharma, a biotechnology company dedicated to improving cancer treatment with innovative therapeutic antibodies that exploit the immune system.
He completed his post-doctoral training at Harvard Medical School, then joined Aix-Marseille University as professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993 before becoming its director from 2008 to 2017. He is also one of the founders of Marseille-Immunopôle, an immunology cluster created in 2014 linking fundamental and therapeutic research, innovation and industrial development on the Aix-Marseille metropole.
Eric Vivier's work focuses on innate immunity and in particular Natural killer and other innate lymphoid cells, at Ciml, at AP-HM and at Innate-Pharma. Professor Vivier has published over 300 scientific articles and is on the list of the most cited researchers